Number of responders · IBD patients
It is very uncertain whether IM erythropoietin changes number of responders ‐ active disease (12 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Serious adverse events · IBD patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of responders · IBD patients
Intravenous preparations may leads to higher number of responders compared with oral preparations (low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · IBD patients
Intravenous preparations may leads to lower withdrawal due to adverse events compared with oral preparations (low certainty).
1 finding from 1 review
Number of responders · IBD patients
1 finding from 1 review
Serious adverse events ‐ active or inactive disease (14 days) · IBD patients
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
1 finding from 1 review
Number of responders ‐ mild to moderate disease (12 weeks) · IBD patients
IV ferric carboxymaltose probably leads to higher number of responders ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (moderate certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (12 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (very low certainty).
1 finding from 1 review
Number of responders ‐ disease activity not stated (12 weeks) · IBD patients
IM erythropoietin + IV iron sucrose showed no clear difference in number of responders ‐ disease activity not stated (12 weeks) compared with IV iron sucrose + IM placebo (low certainty).
1 finding from 1 review
Serious adverse events ‐ disease activity not stated (12 weeks) · IBD patients
1 finding from 1 review
Number of responders · IBD patients
It is very uncertain whether oral ferric maltol changes number of responders ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Treatment success as defined by the authors · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain frequency or change in frequency · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain intensity or change in intensity · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with Crohn's disease
1 finding from 1 review
Treatment success as defined by the authors · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain frequency and intensity (measured as part of the 0‐500 point IBS‐SSS questionnaire) · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
Treatment success as defined by the authors · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found